Publications by authors named "Melanie Spratt"
Pharmacol Res Perspect
May 2021
Article Synopsis
- Omecamtiv mecarbil (OM) is a new drug designed to treat systolic heart failure by improving heart cell performance, and its effects were studied on human failing hearts.
- In experiments with heart muscle samples, OM increased the time it took for the heart to reach peak force and relaxed, but did not significantly boost contractility and helped maintain strength compared to control samples.
- Co-administration of the β-adrenoceptor agonist (-)-noradrenaline countered some negative effects of OM on heart muscle relaxation, indicating potential challenges in using these medications together without increasing side effects.
